LENALIEVA 25 mg contains Lenalidomide, an immunomodulatory anticancer drug (IMiD). It works by modulating the immune system, inhibiting cancer cell proliferation, reducing angiogenesis, and inducing apoptosis of malignant cells. It is a potent analogue of thalidomide with improved efficacy.

Lenalidomide is used in the treatment of:

1.   Multiple Myeloma
      – In combination with dexamethasone or other agents; also for maintenance therapy

2.   Myelodysplastic Syndrome (MDS)
      – With deletion 5q cytogenetic abnormality

3.   Mantle Cell Lymphoma
      – Relapsed or refractory disease

4.   Follicular and Marginal Zone Lymphoma (selected regimens)

Common side effects:

•   Myelosuppression (neutropenia, thrombocytopenia)

•   Fatigue, weakness

•   Diarrhea or constipation

•   Skin rash, itching

•   Muscle cramps

Serious side effects:

•   Thromboembolic events (DVT/PE)

•    Severe infections

•    Liver function abnormalities

•    Secondary malignancies (rare)

Thromboprophylaxis and regular CBC monitoring are essential.

Dosage depends on indication, combination therapy, and renal function.

Common dosing:

•   Multiple Myeloma: 25 mg once daily on Days 1–21 of a 28-day cycle

•   Maintenance therapy: 10–15 mg once daily (dose adjusted)

25 mg is the standard starting dose in many multiple myeloma regimens.


NOTE: This medicine should be taken only under a doctor’s supervision.